Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Jiaqiang Ren

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9129-4849; OpenAlex author ID A5101600045. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 4

  1. Nanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4-Mediated Ferroptosis. Co-author DOI 10.1002/smll.202514973↗
  2. Post-pancreatectomy chemotherapy improves the survival of patients with late-stage but not early-stage pancreatic cancer. Co-author DOI 10.3389/fonc.2026.1744027↗
  3. Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. Co-author DOI 10.1186/s10020-025-01180-y↗
  4. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1002/cam4.7229↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zheng Wu · 3 shared papers, 2024–2026 · strength 0.74
  2. Jiantao Mo · 2 shared papers, 2025–2026 · strength 0.52
  3. Shuai Wu · 2 shared papers, 2024–2025 · strength 0.46
  4. Liang Han · 2 shared papers, 2024–2025 · strength 0.46
  5. Lin Zhang · 1 shared paper, 2026 · strength 0.29
  6. Zheng Wu · 1 shared paper, 2026 · strength 0.29
  7. Zheng Wang · 1 shared paper, 2026 · strength 0.29
  8. Jie Li · 1 shared paper, 2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.